drugset
drugset / Trial / NCT02058472

Pharmacokinetic/Pharmacodynamic & Safety Study of G3041 and SEVIKAR® Tablet in Healthy Adult Volunteers

NCT02058472 ↗

Phase 1 Unknown 30 enrolled Dong-A Pharmaceutical Co., Ltd. Dong-A ST Co., Ltd. · collab
RandomizedCrossoverOpen-labelTreatment

Summary

Study Design : randomized, open label, single-dose, 2-way cross-over design Phase : Phase I

Timeline

Start
2013-12
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 10 mg —
Subject Olmesartan medoxomil Unknown 40 mg —

Indications

No indication recorded.